Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation

oncodaily - Dr. Richard Pazdur, one of the most influential figures in oncology drug regulation, has been appointed Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and […]

AI Summary: The FDA has ushered in a new era in oncology drug oversight by appointing Dr. Richard Pazdur as the director of its Drug Center. The move comes amid agency challenges and staff cuts, promising stabilizing leadership at one of its most influential divisions.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda

FDA announces new regulatory pathway for personalized rare disease therapies

6 months / endpoints / Jared Whitlock

Pazdur vs. Prasad: Can the CDER-CBER dynamic change under new leadership?

6 months / endpoints / Zachary Brennan

Patrick Soon-Shiong: Expanded Access is Not Enough… Withholding FDA Approval Impacts Quality Care

6 months / oncodaily

Richard Pazdur, longtime FDA oncology leader, to head agency’s main drug office

6 months / healthcaredive / Kristin Jensen

FDA taps longtime oncology lead as drug center chief

6 months / beckershospitalreview / Ella Jeffries

Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation